Idexx Laboratories Inc: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 1, 2023 and accepted by EDGAR at Aug 1, 2023, 16:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $943.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $1.84bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $370.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $728.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2023-04-01 to 2023-06-30 | $572.9m | us-gaap:GrossProfit |
| Gross profit | 6 months2023-01-01 to 2023-06-30 | $1.12bn | us-gaap:GrossProfit |
| Research and development | 3 months2023-04-01 to 2023-06-30 | $46.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-01-01 to 2023-06-30 | $91.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | $296.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | $576.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-01 to 2023-06-30 | $10.5m | us-gaap:InterestExpense |
| Interest expense | 6 months2023-01-01 to 2023-06-30 | $23.7m | us-gaap:InterestExpense |
| Income tax | 3 months2023-04-01 to 2023-06-30 | $61.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-01-01 to 2023-06-30 | $115.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | $224.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | $438.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | $2.67 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-06-30 | $5.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | $2.70 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | $5.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 83,983,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 83,980,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | $384.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $67.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2023-01-01 to 2023-06-30 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-06-30 | $132.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $1.18bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $2.87bn | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $883.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $1.78bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-06-30 | $696.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-06-30 | $75.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-06-30 | $1.09bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000874716-23-000100. Last ingested by Listed: Nov 4, 2026, 17:32 ET. Listed shows no prices and gives no investment advice.